Noronex Limited Announces Issuance of 4.9 Million Shares Under Section 708A Exemption

Noronex Confirms Issuance of 4,901,960 Fully Paid Ordinary Shares on 15 July 2026

On 15 July 2026, Noronex Limited confirmed the issuance of 4,901,960 fully paid ordinary shares, with details provided in the Appendix 2A lodged with the ASX on the same date. This Appendix 2A is the standard notification form used by listed companies to report new securities issues, confirming the number of shares issued and their terms. The company update clarifies that this issuance was conducted without a formal disclosure document under Part 6D.2 of the Corporations Act 2001.

Issuing shares without a disclosure document is a common practice in Australian capital markets, especially for placements to sophisticated or professional investors who meet Corporations Act thresholds. The Section 708A(5) notice lodged alongside the Appendix 2A allows these shares to be freely traded on the ASX secondary market, subject to legal compliance. The company did not disclose the issue price, intended use of proceeds, or recipients of the shares in this update.

Implications of Section 708A(5) Notice for Noronex Shareholders

Section 708A(5) of the Corporations Act 2001 provides an exemption permitting shares issued without a disclosure document—such as a prospectus—to be resold on the secondary market without triggering further disclosure requirements, provided certain conditions are met. By issuing this notice, Noronex confirms that the newly issued shares can be freely traded on the ASX. Without this notice, holders of these shares might face restrictions on selling them for a period, limiting liquidity and potentially disadvantaging shareholders.

For existing shareholders, this notice affirms that Noronex has met all legal prerequisites for these shares to enter general circulation. The company confirms compliance with Chapter 2M of the Corporations Act, governing financial reporting, as well as sections 674 and 674A related to continuous disclosure. It also states that no undisclosed information exists that would reasonably affect investors’ assessment of the company’s financial position, prospects, or share rights.

Continuous Disclosure Compliance Confirmed as of 15 July 2026

A key element of the Section 708A(5) notice is Noronex’s formal declaration of compliance with continuous disclosure obligations under sections 674 and 674A of the Corporations Act. Section 674 mandates immediate disclosure of any information likely to materially affect the price or value of the company’s securities, unless an exception applies. Section 674A enforces these obligations through civil penalties.

This declaration assures the market that no material information is being withheld from investors. Noronex further confirms no information has been excluded from continuous disclosure under ASX Listing Rules that investors or their advisers would reasonably require for an informed assessment. This standard confirmation supports the integrity of the exemption and ensures all market participants have access to the same material company information.

Noronex’s Capital Structure After the Share Issuance

Before this issuance, Noronex had 642,965,524 shares on issue, as disclosed in the company’s board and management summary. The update does not clarify whether this figure reflects the total before or after the addition of the 4,901,960 new shares. Investors should consult the Appendix 2A lodged on 15 July 2026 or subsequent registry updates for the precise post-issue share count.

Understanding total shares on issue is critical for assessing dilution. New share issuances reduce existing shareholders’ proportional ownership unless they participate in the raise. Since the issue price was not disclosed, this update alone does not allow calculation of capital raised, implied market capitalization at issuance, or dilution extent. Investors should refer to any accompanying placement documentation or later company disclosures for these details.

Noronex Limited: Company Overview and Board Approval of Share Issue

Noronex Limited is an ASX-listed minerals exploration company headquartered at Suite 1, 295 Rokeby Road, Subiaco, Western Australia. Its board includes Chairman David Prentice, Non-Executive Directors Robert Klug and Piers Lewis, with CEO James Thompson and Chief Geologist Tony Chisnall leading executive management. The company’s registered contact is [email protected] and the website is noronexlimited.com.au.

The 15 July 2026 company update was authorized by the Noronex Board, as required for all ASX-listed entity disclosures. Board authorization indicates directors reviewed and approved the notice contents, including continuous disclosure confirmations. For investor inquiries related to this update, Rowan Harland is the nominated contact via the company’s general email, though no formal title was disclosed.

No Excluded Information Ensures Informed Investment Decisions

A critical requirement for a valid Section 708A(5) notice is confirmation that no information has been excluded from continuous disclosure that investors or their advisers would reasonably need to assess the company. Noronex confirmed in its 15 July 2026 update that no such information exists as of the notice date. This includes the company’s financial position—assets, liabilities, profits, losses, prospects—and the rights attached to the new shares.

This confirmation is essential. Issuing a Section 708A(5) notice while withholding material information could invalidate the exemption, restrict share resale, and expose the company to regulatory action. Noronex’s clear declaration provides market participants confidence that disclosures are current and complete as of the notice date. However, investors should be aware that any material developments after this date must be separately disclosed per continuous disclosure obligations.

Appendix 2A Lodgement and Formal Notification of New Shares to ASX

Appendix 2A is a prescribed ASX Listing Rules form companies must lodge when issuing new securities. It formally notifies the ASX of the number and class of securities issued, issue date, and any conditions or restrictions. Noronex lodged its Appendix 2A on 15 July 2026 for the 4,901,960 fully paid ordinary shares referenced in this update. The Section 708A(5) notice was issued concurrently to enable secondary market trading.

Pairing Appendix 2A with a Section 708A(5) notice is standard in Australia for placements or share issues to eligible investors without a full disclosure document. This process facilitates efficient capital raising while complying with the Corporations Act’s investor protection framework. The company did not disclose terms, conditions, or timelines of any broader capital raising program related to this issuance. Additional context would come from separate disclosures or investor communications.

Risks for Noronex and Considerations for NRX Investors

As an early-stage minerals exploration company, Noronex faces specific risks inherent to its sector and operating environment. Exploration companies typically lack production revenue and rely on equity markets and financing mechanisms—including share issuances like this one—to fund ongoing activities. While necessary for operational progress, new share issuances can dilute existing shareholders’ interests, especially if repeated or priced below market.

Because the issue price and purpose were not disclosed here, investors cannot assess from this update alone whether the terms are favorable or dilutive relative to NRX’s market price. The immediate share price impact is unclear from public information. Investors with NRX exposure or considering investment should review the full Appendix 2A and related disclosures, and consider the broader risks of early-stage minerals exploration firms in Australia’s current resources sector before making decisions.